CYP1A2 (cytochrome P450 family 1 subfamily A member 2)

2003-06-01  

Identity

HGNC
LOCATION
15q24.1
LOCUSID
ALIAS
CP12,CYPIA2,P3-450,P450(PA)
FUSION GENES

Other Information

Locus ID:

NCBI: 1544
MIM: 124060
HGNC: 2596
Ensembl: ENSG00000140505

Variants:

dbSNP: 1544
ClinVar: 1544
TCGA: ENSG00000140505
COSMIC: CYP1A2

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000140505ENST00000343932P05177

Expression (GTEx)

0
10
20
30
40
50
60
70
80

Pathways

PathwaySourceExternal ID
Steroid hormone biosynthesisKEGGko00140
Caffeine metabolismKEGGko00232
Tryptophan metabolismKEGGko00380
Linoleic acid metabolismKEGGko00591
Retinol metabolismKEGGko00830
Metabolism of xenobiotics by cytochrome P450KEGGko00980
Drug metabolism - cytochrome P450KEGGko00982
Steroid hormone biosynthesisKEGGhsa00140
Caffeine metabolismKEGGhsa00232
Tryptophan metabolismKEGGhsa00380
Linoleic acid metabolismKEGGhsa00591
Retinol metabolismKEGGhsa00830
Metabolism of xenobiotics by cytochrome P450KEGGhsa00980
Drug metabolism - cytochrome P450KEGGhsa00982
Metabolic pathwaysKEGGhsa01100
Chemical carcinogenesisKEGGhsa05204
Chemical carcinogenesisKEGGko05204
MetabolismREACTOMER-HSA-1430728
Metabolism of lipids and lipoproteinsREACTOMER-HSA-556833
Arachidonic acid metabolismREACTOMER-HSA-2142753
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)REACTOMER-HSA-2142816
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)REACTOMER-HSA-2142670
Biological oxidationsREACTOMER-HSA-211859
Phase 1 - Functionalization of compoundsREACTOMER-HSA-211945
Cytochrome P450 - arranged by substrate typeREACTOMER-HSA-211897
XenobioticsREACTOMER-HSA-211981
Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2REACTOMER-HSA-211957
Phase II conjugationREACTOMER-HSA-156580
MethylationREACTOMER-HSA-156581
Aflatoxin activation and detoxificationREACTOMER-HSA-5423646

Protein levels (Protein atlas)

Not detected
Low
Medium
High

PharmGKB

Entity IDNameTypeEvidenceAssociationPKPDPMIDs
PA10035bromazepamChemicalPathwayassociated
PA10074escitalopramChemicalClinicalAnnotationassociatedPKPD23859573
PA10075esomeprazoleChemicalLabelAnnotationassociated
PA10804imatinibChemicalClinicalAnnotationassociatedPD30713339
PA124CYP2C19GeneDataAnnotationassociated
PA128CYP2D6GeneDataAnnotationassociated
PA134687924erlotinibChemicalClinicalAnnotationassociatedPK25408262
PA151958383Gastrointestinal Stromal TumorsDiseaseClinicalAnnotationassociatedPD30713339
PA164746058albendazoleChemicalVipGeneassociated18502397
PA164746757tolterodineChemicalLabelAnnotationassociated
PA164760843deferasiroxChemicalClinicalAnnotationassociatedPK25348619, 27193993
PA165946873vemurafenibChemicalMultilinkAnnotationassociated23116250
PA166048714PregnancyDiseaseVariantAnnotationassociatedPD11755554
PA166122590simeprevirChemicalLabelAnnotationassociated
PA166123307insomniaDiseaseClinicalAnnotationassociatedPD29668752
PA166129521sedationDiseaseVariantAnnotationassociatedPD21481946
PA166153431flibanserinChemicalLabelAnnotationassociated
PA166154850rs762551VariantVipGeneassociated11496364, 11763009, 12920202, 15206669, 15505641, 16385402, 16490169, 16522833, 16905781, 17370067, 17611010, 17688403, 18075470, 18180754, 18466106, 19636338, 21121774, 10889552
PA166154874rs2069514VariantVipGeneassociated12732846, 15505641, 15564895, 16385402, 20390257, 10101295
PA166154935rs12720461VariantVipGeneassociated12920202
PA166163418rucaparibChemicalLabelAnnotationassociated
PA193HTR2AGeneDataAnnotationassociated
PA312SLC6A4GeneDataAnnotationassociated
PA443227Abortion, SpontaneousDiseaseClinicalAnnotation, VariantAnnotationassociatedPKPD11755554, 15849225, 17370067
PA443434Arthritis, RheumatoidDiseaseClinicalAnnotationassociatedPKPD18496682, 19581389
PA443560Breast NeoplasmsDiseaseVariantAnnotationnot associated17507615
PA443636Carotid Artery DiseasesDiseaseVariantAnnotationnot associatedPD26526111
PA443771ConfusionDiseaseVariantAnnotationassociatedPD21481946
PA443937Drug ToxicityDiseaseVariantAnnotationassociatedPD21481946
PA444065EpilepsyDiseaseClinicalAnnotationassociatedPK26762380
PA444354HeadacheDiseaseVariantAnnotationassociatedPD21481946
PA444993Muscle RigidityDiseaseVariantAnnotationassociatedPD21481946
PA445019Myocardial InfarctionDiseaseClinicalAnnotation, VariantAnnotationassociatedPD16522833
PA445043Opioid-Related DisordersDiseaseVariantAnnotationnot associatedPK17178267
PA445629SeizuresDiseaseVariantAnnotationassociatedPD23601795
PA445802TachycardiaDiseaseVariantAnnotationassociatedPD21481946
PA445876Tobacco Use DisorderDiseaseVariantAnnotation, VipGeneassociatedPK17370067, 18687246
PA446432beta-ThalassemiaDiseaseClinicalAnnotationassociatedPK25348619, 27193993
PA447216SchizophreniaDiseaseClinicalAnnotation, VariantAnnotationambiguousPKPD15505641, 17611010, 18223460, 19000940, 21481946, 23601795
PA447278DepressionDiseaseDataAnnotation, VariantAnnotationassociatedPD27800629
PA447321Depressive Disorder, MajorDiseaseClinicalAnnotation, DataAnnotationassociatedPKPD21121774, 21593735, 23859573
PA448015acetaminophenChemicalLiterature, MultilinkAnnotation, Pathwayassociated19219744, 26049587
PA448710caffeineChemicalClinicalAnnotation, MultilinkAnnotation, VariantAnnotation, VipGeneambiguousPKPD10101295, 10233211, 11755554, 12920202, 15849225, 16522833, 17370067, 17507615, 20390257, 21593735, 29282363, 29668752, 8491061, 8689941
PA448785carbamazepineChemicalClinicalAnnotation, MultilinkAnnotationassociatedPK26762380
PA448964chlorpromazineChemicalClinicalAnnotationassociatedPD17611010
PA449048clomipramineChemicalPathway, VariantAnnotationassociatedPD27800629
PA449053clopidogrelChemicalClinicalAnnotation, Pathway, VariantAnnotation, VipGeneambiguousPKPD18687246, 20938371, 21148426, 24262617, 26526111
PA449061clozapineChemicalClinicalAnnotation, VariantAnnotation, VipGeneassociatedPKPD19593168, 20125119, 21481946, 23601795
PA449197dacarbazineChemicalVariantAnnotationassociatedPK27428168
PA449233desipramineChemicalPathwayassociated
PA449409doxepinChemicalPathwayassociated
PA449646flecainideChemicalVariantAnnotationassociatedPK22718623
PA449676fluphenazineChemicalClinicalAnnotationassociatedPD17611010
PA449690fluvoxamineChemicalMultilinkAnnotation, VipGeneassociated11763009, 8823236
PA449969imipramineChemicalPathwayassociated
PA450180lansoprazoleChemicalVipGeneassociated18502397
PA450192leflunomideChemicalClinicalAnnotationassociatedPKPD18496682, 19581389
PA450401methadoneChemicalVariantAnnotationnot associatedPK17178267
PA450688olanzapineChemicalClinicalAnnotation, LabelAnnotation, VariantAnnotation, VipGeneambiguousPKPD18223460, 19000940, 19636338, 23492908
PA450704omeprazoleChemicalVipGeneassociated18502397
PA450801paroxetineChemicalClinicalAnnotation, Pathway, VipGeneassociatedPKPD21121774, 21593735
PA451103primaquineChemicalVipGeneassociated18502397
PA451201quetiapineChemicalVariantAnnotationassociatedPK25025989
PA451581tamoxifenChemicalPathwayassociated23962908
PA451647theophyllineChemicalPathway, VipGeneassociated18466106
PA451666thioridazineChemicalClinicalAnnotationassociatedPD17611010
PA451771trifluoperazineChemicalClinicalAnnotationassociatedPD17611010
PA451906warfarinChemicalMultilinkAnnotation, VipGeneassociated17392729, 8689941, 8723744
PA452233antipsychoticsChemicalClinicalAnnotation, VipGeneassociatedPD19593168, 15505641, 17611010
PA452604xenobioticsChemicalVariantAnnotationassociatedPK12920202

References

Pubmed IDYearTitleCitations
379064192024Habitual coffee consumption and risk of dementia in older persons: modulation by CYP1A2 polymorphism.0
379064192024Habitual coffee consumption and risk of dementia in older persons: modulation by CYP1A2 polymorphism.0
362392902023The influence of the CYP1A2-163 C>A polymorphism on the hemostatic response to exercise following caffeine supplementation.0
367011572023CYP1A2 Genetic Variation, Coffee Intake, and Kidney Dysfunction.5
375112392023Hydration and Structural Adaptations of the Human CYP1A1, CYP1A2, and CYP1B1 Active Sites by Molecular Dynamics Simulations.1
362392902023The influence of the CYP1A2-163 C>A polymorphism on the hemostatic response to exercise following caffeine supplementation.0
367011572023CYP1A2 Genetic Variation, Coffee Intake, and Kidney Dysfunction.5
375112392023Hydration and Structural Adaptations of the Human CYP1A1, CYP1A2, and CYP1B1 Active Sites by Molecular Dynamics Simulations.1
345647062022CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study.8
353385822022Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6-hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots.1
353803342022Contribution of CYP19A1, CYP1A1, and CYP1A2 polymorphisms in coronary heart disease risk among the Chinese Han population.0
359056562022Functional single-nucleotide polymorphism (rs762551) in CYP1A2 gene affects white coffee intake in healthy 20- to 40-year-old adults.0
360114092022Relationship between Nutrition, Lifestyle, and Neurodegenerative Disease: Lessons from ADH1B, CYP1A2 and MTHFR.0
345647062022CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study.8
353385822022Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6-hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots.1

Citation

Dessen P

CYP1A2 (cytochrome P450 family 1 subfamily A member 2)

Atlas Genet Cytogenet Oncol Haematol. 2003-06-01

Online version: http://atlasgeneticsoncology.org/gene/40236/css/lib/favicon/favicon-32x32.png